Inactive Instrument

News Motif Bio plc Nasdaq

Equities

US6197841017

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

MOTF BIO : BiVictriX Debuts on London's AIM Segment After $10 Million IPO	21-08-11	MT
Motif Bio plc Announces Board Appointments	21-06-14	CI
BiVictriX Therapeutics Ltd. cancelled the acquisition of Motif Bio plc in a reverse merger transaction.	21-06-13	CI
Motif Bio plc Reports Earnings Results for the Full Year Ended December 31, 2020	21-05-10	CI
Motif Bio : 2020 Annual Report and Accounts	21-05-10	PU
Motif Bio plc Announces Board Changes	21-05-10	CI
Orange Avenue Technologies LLC entered into a Stock Purchase Agreement to acquire Motif BioSciences, Inc. from Motif Bio plc	21-02-25	CI
Motif Bio : Signs Reverse Takeover of Antibody-Drug Conjugate Company	21-01-27	MT
BiVictriX Therapeutics Ltd. entered into a sale and purchase agreement to acquire Motif Bio plc for £5.5 million in a reverse merger transaction.	21-01-26	CI
Motif Bio plc Reports Earnings Results for the Half Year Ended June 30, 2020	20-10-12	CI
Motif Bio : Results of AGM	20-09-30	PU
Motif Bio : Notification of Interim Results	20-09-23	PU
Motif Bio : Annual Report and Accounts & Notice of AGM	20-09-09	PU
Motif Bio plc Reports Earnings Results for the Full Year Ended December 31, 2019	20-09-01	CI
Motif Bio : Delay in publication of Final Results	20-06-22	PU
Motif Bio plc Announces Delay in Publication of Final Results for the Year Ended 31 December 2019	20-06-22	CI
Motif Bio : Business Update and Appointment of Strategic Adviser	20-06-02	AQ
Motif Bio Appoints Adviser for Reverse Takeover Candidate	20-06-01	CI
Motif Bio : Exercise of Warrants	20-05-18	AQ
Motif Bio : Placing to raise GBP650,000	20-05-06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Motif Bio plc Nasdaq

Equities

US6197841017

Summary

Filters